Company Description

Brink Biologics, a a NantKwest affiliate, holds the exclusive non-clinical rights to the NK-92ﾮ cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity assays.